Niagen Bioscience (NAGE) Other financing activities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Other financing activities of $111000.0 for Q1 2026, down 96.44% year-over-year from $3.1 million in Q1 2025, and down 51.32% quarter-over-quarter from $228000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Other financing activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Other financing activities for 12 consecutive years, with $111000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 96.44% year-over-year to $111000.0; the TTM figure through Mar 2026 stood at $4.2 million (down 50.35% YoY), while the FY2025 annual figure was $7.2 million, up 33.39% from the prior year.
- Other financing activities slipped to $111000.0 in Q1 2026 per NAGE's latest filing, from $228000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3.8 million in Q4 2024 and bottomed at $111000.0 in Q1 2026.
- Historically, Other financing activities has averaged $1.6 million across 3 years, with a median of $820500.0 in 2024.
- Annual changes were most pronounced in 2025 — Other financing activities jumped 527.42% — and 2026, when it sank 96.44%.
- Niagen Bioscience's Other financing activities stood at $3.8 million in 2024, then slumped by 93.99% to $228000.0 in 2025, then sank by 51.32% to $111000.0 in 2026.
- Business Quant data shows NAGE's Other financing activities at $111000.0 in Q1 2026, $228000.0 in Q4 2025, and $152000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 206,000.00 |
| Mar 31, 2026 | 111,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 598,000.00 |
| Dec 31, 2021 | 130,000.00 |
| Sep 30, 2021 | 341,000.00 |
| Jun 30, 2021 | 391,000.00 |
| Mar 31, 2021 | 8.63 Mn |
| Dec 31, 2020 | 1.26 Mn |
| Sep 30, 2020 | 547,000.00 |
| Jun 30, 2020 | 2.18 Mn |
| Mar 31, 2020 | 132,000.00 |
| Dec 31, 2019 | 460,000.00 |
| Sep 30, 2019 | 335,000.00 |
| Jun 30, 2019 | 164,000.00 |